Aurobindo Pharma Financial Statements

Aurobindo Pharma (AUROPHARMA) reported revenue of ₹323.46B in FY2025 with net income of ₹34.86B. Total assets stood at ₹497.85B and free cash flow was ₹19.57B.

Aurobindo Pharma Income Statement

Hover the chart icon for year-over-year change.

FY 2024 – FY 2025

Item	Chart	2024	2025
Revenue		295.59B	323.46B
Cost of Rev. Cost of Revenue		-126.03B	-130.26B
Gross Profit		169.56B	193.19B
SGA Sales, General & Admin		-105.56B	-121.15B
Op. Income Operating Income		48.79B	55.55B
PBT Profit Before Tax		43.97B	50.66B
Net Income		31.69B	34.86B
Dil. Shares Diluted Shares		585.85M	582.87M
Diluted EPS		54.16	59.81

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Aurobindo Pharma's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Aurobindo Pharma Balance Sheet

Hover the chart icon for year-over-year change.

FY 2024 – FY 2025

Item	Chart	2024	2025
Curr. assets Total current assets		242.06B	271.62B
Non-curr. assets Total non-current assets		208.66B	226.23B
Total assets		450.72B	497.85B
Curr. liabilities Total current liabilities		121.99B	146.82B
Non-curr. liab. Total non-current liabilities		30.22B	24.56B
Total liabilities		152.21B	171.38B
Total equity		298.51B	326.47B
Total liab. & eq. Total liabilities & equity		450.72B	497.85B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Aurobindo Pharma's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Aurobindo Pharma Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2024 – FY 2025

Item	Chart	2024	2025
Net Income		43.80B	50.66B
Operating CF Cash flow Operating Activities		24.35B	39.25B
Capex Investments in PPE		-27.80B	-19.68B
Investing CF Cash flow Investing Activities		-42.56B	-18.76B
Dividend Paid		-2.64B	-10.40M
Financing CF Cash flow Financing Activities		8.00B	1.20B
Cash (start) Cash at beginning of period		43.92B	33.85B
Cash (end) Cash at end of period		33.85B	55.64B
FCF Free Cash Flow		-3.46B	19.57B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Aurobindo Pharma's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025